To jump to a specific SUGDIS publication, click on the title:
Current Literature and
Information for Pharmacists (CLIPS)
New Drug FAX Sheet
Pharmacy Precis
2nd Quarter Index
| Issue Number |
Date | Title |
|---|---|---|
34 |
Aug 4 | Aspirin Resistance and Cardiovascular Prevention |
33 |
Jul 30 | An Overview of Diabetes and Blood Glucose Meters |
32 |
Jul 28 | Prevention is Key in Fighting Obesity |
31 |
Jul 21 | Pharmacists' Interventions Leads to Improved Patient Care |
30 |
Jul 7 | Point / Counterpoint: Vancomycin for C. difficile |
29 |
Jul 7 | Point / Counterpoint: Metronidazole for C. difficile |
28 |
Jun 30 | American College of Clinical Pharmacy's Recommendations for Competencies for Clinical Pharmacists |
27 |
Jun 23 | Approaches to Insomnia Diagnosis and Treatment |
26 |
Jun 16 | Focus on Investigational Agents to Treat Osteoporosis |
25 |
Jun 12 | Aprotinin Increases Death: Study Results |
24 |
Jun 9 | 2008 Revisions to USP Chapter <797> |
23 |
Jun 2 | Cardioprotictive Benefits with Omega-3 Fatty Acids |
22 |
May 26 | Dispensing Medication Guides and Pharmacists' Responsibilities |
21 |
May 19 | Treatments for Pain Associated with Diabetic Peripheral Neuropathy |
20 |
May 12 | Cutaneous Reactions to Methylphenidate Transdermal System |
19 |
Apr 28 | Dementia Treatment Guidelines |
18 |
Apr 24 | A Review of Smoking Cessation Therapies |
17 |
Apr 21 | Antithrombotic Therapy in Patients with Atrial Fibrillation |
16 |
Apr 14 | Treating Delirium in the Elderly: Atypical Antipsychotics |
15 |
Mar 31 | Overview of Restless Leg Syndrome |
14 |
Mar 24 | Quinine and Alternatives for Nocturnal Leg Cramps |
13 |
Mar 17 | Statins to Treat Heart Failure |
12 |
Mar 3 | Patient Education |
11 |
Feb 26 | Survey Results Indicated the Importance of Clinical Pharmacists |
10 |
Feb 25 | Patient Complications Following Bariatric Surgery |
9 |
Feb 19 | Herpes Zoster and Zostavax® Use |
8 |
Feb 18 | Chronic Insomnia: A Review of Treatments |
7 |
Feb 4 | Management of Postoperative Nausea and Vomiting |
6 |
Jan 28 | Antifungal Resistance |
5 |
Jan 24 | Vytorin® in the News |
4 |
Jan 21 | Diagnosing and Managing Adolescent Depression in Primary Care Settings |
3 |
Jan 14 | Understanding and Treating Xerostomia |
2 |
Jan 7 | Incorporating Complementary and Alternative Medicine into Curriculum and Practice |
1 |
Jan 3 | Another TZD Adverse Outcome Study |
| Issue Number |
Date | Title |
|---|---|---|
32 |
Jul 23 | Vitamin D Therapy |
31 |
Jul 14 | New Drug Approvals |
30 |
Jul 8 | Boxed Warning Added to Fluoroquinolones |
29 |
Jun 27 | Aleskiren (Tekturna®) |
28 |
Jun 24 | Colesevelam (Welchol®) for Diabetes |
27 |
Jun 24 | Trospium Extended-Release (Sanctura®-XR) |
26 |
Jun 20 | Desvenlafaxine (Pristiq®) |
25 |
Jun 19 | Boxed Warnings Added to 'Typical' Antipsychotics |
24 |
May 21 | Azathioprine Packaged Instead of Minocycline |
23 |
May 21 | Boxed Warning Added to Enbrel® Labeling |
22 |
May 21 | Trasylol® Stocks Removed by Manufacturer |
21 |
May 8 | Levocetirizine (Xyzla®) |
20 |
May 5 | New Drug Approvals |
19 |
Apr 17 | Heparin Alternatives |
18 |
Apr 10 | Potential Association of Mycophenonate Use and Progressive Multifocal Leukoencephalopathy (PML) |
17 |
Apr 10 | Lung Malignancies Associated with Exubera (Insulin Human [rDNA Origin]) Inhalation Powder |
16 |
Apr 10 | Possible Impurity in Datomycin Injections for ReadyMED Pumps |
15 |
Apr 7 | New Drug Approvals |
14 |
Mar 28 | Possible Increased MI Risk with NRTIs |
13 |
Mar 28 | Possible Cancer Risk Increase with Regranex® |
12 |
Mar 27 | New Singulair® Safety Information |
11 |
Mar 19 | Tiotropium Use Associated with Stroke in Pooled Analyses |
10 |
Mar 17 | Two Additional Trials Suggest ESAs Shorten Survival Time in Cancer Patients |
9 |
Mar 12 | Herparin "Shortage" Update |
8 |
Mar 12 | Life-Threatening Adverse Events and Death Associated with Tussionex Pennkinetic Extended-Release Suspension |
7 |
Mar 10 | New Drug Approvals |
6 |
Mar 7 | Additional Trasylol® Safety Data |
5 |
Mar 6 | New Tamiflu® Safety Information |
4 |
Feb 11 | New Drug Approvals |
3 |
Feb 8 | Severe Adverse Reactions Following Botulinum Toxin Administration |
2 |
Feb 1 | Chantix® Safety Update |
1 |
Jan 7 | Severe Bone, Joint and/or Muscle Pain Associated with Bisphosphonate Use |
Return
to Top
| Issue Number |
Date | Title |
|---|---|---|
| 1 | February |
Return
to Top